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esponsibility of Inst
ess under CC BY-NC-Abstract Clausenamide (clau) is one of seven novel compounds isolated from Clausena lansium (Lour)
skeels. Clau is unusual in that it contains 4 chiral centers yielding 8 pairs of enantiomers. After
identiﬁcation of the conﬁguration of these enantiomers, the synthesis of 16 enantiomers, including
optically active clau and (þ) and (–)clau was carried out. During this study, many stereochemical and
synthetic difﬁculties were solved and the Baldwin principle was updated. Production scale is now
sufﬁcient to meet the needs of clinical practice. In a pharmacological study numerous models and
indicators showed that (–)clau is the active enantiomer, while (þ)clau is inactive and elicits greater
toxicity than (–)clau. The principal pharmacological effects of (–)clau are to increase cognition,
demonstrated in ten models of memory impairment, as well as to inhibit β-amyloid (Aβ) toxicity,
blocking neuroﬁbrillary tangle formation by inhibiting the phosphorylation of tau protein. This anti-
dementia effect is characterized by increased synaptic plasticity both in efﬁcacy and in structure and
provides new support for the theory that synaptic loss is the main cause of dementia. (–)Clau is considered
to be a promising drug candidate for treatment of Alzheimer's disease and other neurodegenerative
disorders.
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Alzheimer's disease (AD) is an age-related neurodegenerative
disease characterized by progressive decline of cognitive function,
appearance of senile plaques, neuroﬁbrillary tangles, and loss of
neurons and synapses. Few drugs have been found to be effective
and safe for the treatment of AD.
In China, in recent years increasing emphasis has been placed on
research on natural products and traditional Chinese medicine
(TCM). About 150 new drugs have been developed with more
than 20 that affect the nervous system. (–)Clausenamide (clau) is the
ﬁrst chiral anti-dementia compound isolated from Clausena lan-
sium, an evergreen plant distributed mainly in Asia and Paciﬁc
region. The percolate of the leaves of C. lansium was described in
ancient TCM books (Ben Cao Qiu Yuan) for the treatment of edema
with yellow tinge of skin, and the edible fruit of C. lansium is quite
popular in southern China. Therefore, we believed that it is safe and
may have some therapeutic effects. This paper highlights recent
advances in the chemistry, pharmacology and pharmacokinetics of
(–)clau in anti-dementia research, some of which are very new.2. Chemistry of clau
From the aqueous extract of the leaves of C. lansium, chemists isolated
seven amides, one of which, clau, is a γ-lactam with four asymmetric
carbons yielding 16 enantiomers. The pharmacological evaluation,
synthesis and identiﬁcation of the 16 enantiomers were completed in
Prof. Liang Huang's laboratory (Institute of Materia Medica, Chinese
Academy of Medical Sciences and Peking Union Medical College,
Beijing, China). The structures and conﬁgurations of the 16 enantio-
mers are shown in Fig. 1. A pharmacological study showed that
racemic clau had nootropic effects as demonstrated by behavioral and
electrophysiological experiments. Then, a question was advanced as to
which one, (þ) or (–)clau, is the bioactive isomer. Bayer company and
our institute attempted to synthesize racemic clau and resolve the (–)
and (þ)enantiomers. Dr. Hartwig of Bayer Co. reported a 10-step
synthesis of racemic clau by building the skeleton ﬁrst through
NCQO and C4/C5-linking followed by stepwise stereoselective
introduction of substituents. The overall yield was 5.7%–6.4%. Liang
Huang et al.1 reported a biomimetic synthetic route based upon the
biogenetic relationship perceived among the seven amides isolated, and
the total synthesis was reduced to 5 steps with an overall yield of 15%–
17%. The two synthetic schemes are shown in Scheme 1.
For ensuring (–)clau to be effective, safe, stable and reliable in
clinical practice, methods for chiral separation, puriﬁcation and
quality control were developed, which include rapid and reliable
method for isomer separation by capillary electrophoresis and chiral
column chromatography. Optical purity and the identity of impurities
were determined by high performance liquid chromatography
(HPLC). The results showed that complete separation of (–)clau
and (þ)clau was achieved with the optical purity reaching 99%. The
single impurity was identiﬁed as (–)epi clau with an approximate
content of 0.3%.3. Pharmacological effects
3.1. Effect on memory impairments
Ten animal models were used to evaluate the effect of (–)clau
on memory impairment include APP-transgenic mice, aged rats(24–27 months), diabetic mice, cerebral ischemic-reperfusion rats,
β-amyloid (Aβ) and other 5 chemically-induced memory impairment
models. Oral administration of (–)clau at a dose of 5–10 mg/kg
signiﬁcantly improved learning and memory2,3. The effective
dosage was equal to that of donepezil and much more potent than
piracetam.
3.2. Effect on long term potentiation (LTP) of synaptic
transmission
Considerable evidence supports the idea that long-lasting activity-
dependent plasticity of synaptic transmission is of fundamental
importance in the development of neural circuitry and storage of
information. As a typical form of this plasticity, LTP in the
hippocampus is the neural basis of learning and memory. It is also
a good experimental model for investigating cognitive function at
cellular and synaptic levels. Surgery and electrophysiological
recordings were conducted as described in our publications4–7.
By comparing (–) and (þ)clau, the following results were obtained:
(–)clau at concentration of 107–105 mol/L increased basic synaptic
transmission and the amplitude of LTP induced by high frequency
stimulation in anesthetized or freely moving rats in a concentration-
dependent and time-dependent manner (Figs. 2 and 3). (þ)Clau
showed no effects on LTP. There are two forms of LTP: one is
dependent on the activation of the N-methyl-D-aspartate (NMDA)
receptor, and the other is mediated by entry of calcium via a voltage-
dependent calcium channel (VDCC). It was demonstrated that (–)clau-
induced LTP was inhibited by nimodipine, a speciﬁc antagonist of the
L-type VDCC. But APV, a speciﬁc antagonist of the NMDA receptor,
had no inhibitory effect on (–)clau-induced LTP, indicating that
VDCCs rather than NMDA receptors are required for an effect of
(–)clau to take place. We have also evaluated the 16 enantiomers of
clau by testing their effects on synaptic transmission in the hippocam-
pus and found that four had potentiation effects. Nimodipine, piracetam
and donepezil showed no effect on LTP8.4. Nootropic mechanism of (–)clau
As mentioned above, (–)clau improved learning and memory in 10
models of memory impairment and increased synaptic plasticity in
anesthetized or freely moving rats. For elucidation of the nootropic
mechanism of (–)clau, many studies were conducted and revealed
that a moderate increase of [Ca2þ]i, stimulation of central
cholinergic neurons, and enhancement of synaptogenesis are
important factors in inducing the nootropic effects of (–)clau.
4.1. (–)Clau increased [Ca2þ]i at a moderate level
Calcium ions are ubiquitous intracellular second messengers that
act as key regulators of innumerable processes, such as the control
of cell growth and differentiation, maintenance of cytoskeletal
integrity, learning, memory and synaptic activity.
There are many mechanisms by which calcium levels are
modulated, for example, calcium inﬂux and accumulation, Ca2þ
clearance, cytoplasmic Ca2þ buffering, and controlling the temporal
and special distribution of Ca2þ in the neurons. These mechanisms
maintain [Ca2þ]i at an extremely low level, so that a relatively small
or localized change in [Ca2þ]i can be used by the cell as a signal to
trigger distinct physiological processes. For a drug, elevation of
[Ca2þ]i to a moderate level is an important effect that might activate
neuroprotective pathway. The well-known ability of KCl to promote
Figure 1 The structures and conﬁgurations of the 16 enantiomers.
Recent advances in the study of (–)clausenamide 419survival of neurons in cell culture may be explained by the moderate
elevation of [Ca2þ]i. Several neurotrophic factors such as nerve
growth factor (NGF) and brain derived nootropic factor (BDNF) are
also known to induce small elevations of [Ca2þ]i in neurons in which
they promote long term survival and protect against excitotoxic
insults9,10.
In our investigation of (–)clau-induced Ca2þ signaling in primary
cultures of cortical neurons by using laser confocal microscopy, it
was demonstrated that (–)clau induced only a small [Ca2þ]i change
after application of 20 mmol/L Mg2þ extracellularly11. In this
condition, (–)clau could improve learning and memory, increase
synaptic plasticity in both efﬁcacy and structure, increase acetylcho-
line release and activate nootropic signal transduction pathways.4.2. Stimulation of central cholinergic neurons
The deﬁcits in cognition and memory storage observed in age-
associated memory impairment (AAMI) and AD are associated
with a deﬁciency of the central cholinergic system. Thus,
cholinergic stimulants may be therapeutically used in the treatmentof AD patients. It was demonstrated that a single administration of
(–)clau (10, 20, 50 ng/kg) signiﬁcantly ameliorated the reduction
of acetylcholine induced by anisodine (a M-cholinergic receptor
antagonist, 10 mg/kg i.p.) in a dose-dependent manner. But
(þ)clau had no effect on acetylcholine levels when administered
in similar doses. Further study showed that (–)clau increased
choline acetyltransferase (ChAT) activity in cortex, hippocampus
and striatum signiﬁcantly. As ChAT is a key enzyme for synthesis
of Ach, the protective effect of (–)clau on Ach reduction by
anisodine is likely the result of increased Ach synthesis and
release12,13. Furthermore, (–)clau exhibited neurotrophic action,
i.e., stimulated the proliferation of cholinergic neurons and
supported survival and neurite outgrowth of cholinergic neurons.
(–)Clau and NGF had a similar neurotrophic action but were
mediated by different mechanisms.4.3. (–)Clau increased synaptogenesis
Basic and clinical studies in recent years have shown that senile
plaque and neuroﬁbrillary tangle are not related to the degree of
Scheme 1 Synthesis schemes of racemic clau. A, Hartwig's retrosynthesis scheme of racemic clau; B, Liang Huang's synthesis scheme of racemic clau.
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other neurodegenerative diseases. Synaptic loss suspended signal
deliver and transduction, damaged the receptors, ion channels and
proteins contained in front and posterior synaptic membranes, leading
to neuropsychological dysfunction, memory deﬁcit and dementia.
Therefore, synaptic loss was considered as a main cause of dementia,
and even some scientists proposed that ‘synaptic loss¼AD’. For this
reason, the new strategy for treatment of AD is limiting synaptic loss
and increasing synaptogenesis14,15.
In order to ascertain the basis of the morphology of nootropic
action of (–)clau, the effect of (–)clau on brain development was
studied. (–)Clau at dosages of 5 and 10 mg/kg by gavage to mice
once a day for 4 weeks facilitated learning and memory acquisition in
step-down and step-through tests and increased the thickness of
cerebral cortex, and increased synapse density signiﬁcantly in the
dentate cells over pyramidal cells in the hippocampal region, based
on a quantitative technique of synapse analysis. In another study,
(–)clau increased mossy ﬁber sprouting and the expression of growth-
associate protein (GAP-43). Synapses are the essential structure in the
central nervous system (CNS) through which signals are transmitted,
processed and integrated among neurons. (–)Clau increased synaptic
plasticity in both efﬁcacy and structure which provide morphological
and physiological evidence to support nootropic effects of (–)clau.5. Activation of learning and memory signal transduction
induced by (–)clau
Study of the learning and memory signal transduction pathway is
essential for elucidation of nootropic mechanisms. This study canprovide us much information, for example, in ﬁnding a target
receptor, genes that encode key proteins, crosstalk between
different signaling cascades, explanation for long term memory
formation at the molecular level, and so on. There are two kinds of
nootropic signaling pathways induced by (–)clau.5.1. Phospholipase C–protein kinase C (PLC–PKC)-mediated
signaling pathway
Studies have shown that (–)clau has no speciﬁc binding to NMDA
receptors, but it could increase NMDA receptor density and
glutamate release. Furthermore, (–)clau was shown to be a
potassium channel antagonist which blocks potassium efﬂux and
induced membrane depolarization. The latter effect could remove
Mg2þ around NMDA receptors, promoting glutamate binding to
the NMDA receptor. After ligand-induced receptor activation, the
signal transduction was initiated beginning with the activation of
PLC via G protein. PLC hydrolyzes phosphatidylinositol 4,5-
bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and
diacyl glycerol (DAG), the latter activates PKC which in turn
phosphorylates a series of protein kinases including cAMP-
response element binding protein (CREB) in nuclei. Phosphory-
lated CREB transcribed memory-related genes. In this study, the
gene products were zif/268 and BDNF.5.2. CaMKII–ERK mediated signaling pathway
Britain in 1997 reported that mitogen-activated protein kinase
kinase (MAPKK) played a role in modulating synaptic plasticity.
Figure 2 Effect of (–) or (þ)clau on LTP in the DG of (a)
anesthetized and (b) freely moving rats induced by high frequency
stimuli (HFS). (a): LTP was induced using an HFS protocol of 100 Hz
(10 bursts of 5 stimuli, 0.2 ms duration, 200 μs interburst interval).
HFS was applied 15 min after drug administration. (b): The stimula-
tion and recording electrodes were ﬁxed to the skull using acrylic
dental cement and then all rats were housed individually on a 12-h
light/dark cycle with food and water available ad libitum, and tested
during the light cycle. All rats were injected with 16 U penicillin to
prevent infection, allowed to recover from surgery for 7 days, and
evaluated to ensure normal mobility. (–)Clau and (þ) clau at a dose of
8 mg/kg was administrated orally. From day 8, the population spike
were evoked by stimulation at low frequency (0.33 Hz, duration
200 μs), 10 evoked responses were averaged as the efﬁcacy of
synaptic transmission.
Figure 3 Effect of (–)clau on LTP with different doses. (–)Clau was
administered by intracerebroventricular injection and the population
spike amplitude was recorded every 5 min. ***Po0.001 vs control
animals. f-EPSP: ﬁeld-excitatory postsynaptic potential.
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several protein kinases upstream, such as protein kinase A (PKA),
PKC, calmodulin-dependent protein kinase (CaMK) II, CaMK IV,
etc. Among them, CaMK II is the main protein contained in
postsynaptic density (PSD) preparations, reaching 20–40%.
(–)Clau (105 mol/L) increased the population spike (PS) of the
hippocampal dentate gyrus, with peaks at 5 and 30 min. (–)Clau
also promoted the transient enhancement of upstream Ca2þ and
activated CaMKII at the 2nd minute in vitro. The downstream
protein, CREB was phosphorylated at the 9th minute. Pretreatment
with KN93, a CaMKII antagonist and PD98059, a ERK inhibitor,
could partially block the (–)clau-induced LTP. The ﬁnal gene
products were zif/268 and BDNF, which are responsible for long
term memory formation and LTP.6. Preclinical safety evaluation
For evaluating the safety of (–)clau, acute and chronic toxicity
were carried out. In mice, the LD50 of (–)clau by oral adminis-
tration was 5290 mg/kg. Rats and beagle dogs were used in a
chronic study for 7 months. Results with rats showed that there
was no apparent toxicity at the dose of 40 and 80 mg/kg. (–)Clau
produced mild toxicity at a dose of 160 or 80 mg/kg, as indicated
by hepatic steatosis and focal necrosis. These pathological changes
could be reversed after drug withdrawal. The ‘no observed effect
level’ (NOEL) in rats (80 mg/kg) was equal to 48 times and 7.9
times the recommended clinical dosage, according to a body
weight and body surface area conversion chart. In beagle dogs
(–)clau showed minor toxicity as indicated by increased serum
urea nitrogen and the level of ketone in the urine. The NOEL was
60 mg/kg which was equivalent to 21 times the recommended
clinical dosage. All of these studies indicated that (–)clau is a safe
candidate for the treatment of dementia.7. The pharmacokinetics of clau
The pharmacokinetics of clau enantiomers and their metabolites
were investigated in Wistar rats and beagle dogs. After intravenous
and oral administration of (–) and (þ)clau, their major metabolites
were determined simultaneously by reverse-phase HPLC and
HPLC–MS/MS. As the pharmacologic effects of clau were
investigated in rats, the pharmacokinetic proﬁles of clau in rats
were reported here16–18.
7.1. Main pharmacokinetic parameters
After intravenous and oral administration at dose of 80 and
160 mg/kg of each enantiomer, plasma concentrations of (–) and
(þ)clau and its major metabolites were determined simultaneously
by reverse-phase HPLC with UV detection. The mean plasma
levels of (þ)clau were higher at all time points than those of
(–)clau. (þ)Clau exhibited greater Tmax, Cmax, t1/2β, AUC0–12 h,
AUC0–1 and smaller CL (or CL/F) and Vd (or Vd/F) than its
antipode, implying that the absorption, distribution and elimination
of (–)clau were more rapid than those of (þ)clau.
7.2. Tissue distribution
Fifteen min after oral administration, (–) and (þ)clau were found
in brain, liver, intestine, stomach, ovary, testis, spleen, kidney,
Shi-feng Chu, Jun-tian Zhang422heart, fat, muscle, lung and spinal cord. The content of (–)clau
in target tissues (hippocampus, cortex, cerebellum) was higher
than that of (þ)clau. But at 4 h post-dose, the results were
reversed.
7.3. Plasma protein binding
When (–)clau at concentrations of 5 and 20 μmol/L were added to
rat plasma, the mean percentage of (–)clau in the binding form was
28.570.6%, while the mean percentage of (þ)clau was
38.0572.6%, which was signiﬁcantly higher than that of its
antipode. But similar results were not observed in rabbit plasma, in
which the bound fractions of both (þ) and (–)clau were higher
than that in rat plasma. There were signiﬁcant species difference in
the binding of (–)clau between rabbits (47.274.9%) and rat
(28.570.6%).
7.4. Metabolites of clau
Metabolites of (–) and (þ)clau in urine, feces, bile and blood were
detected using RP-HPLC–DAD. Eight metabolites, including 6-
hydroxyl-clau (CM1), 5-hydroxyl-clau (CM2), 4-hydroxyl-clau
(CM3), 4,6-dihydroxyl-clau (CM4), 4-phenyl-m-hydroxyl-clau
(CM5), 4,7-phenyl-m-hydroxyl-clau (CM6), 3-dihydroxyl-clau
(CM7) and N-demethyl-clau (CM8) were found and identiﬁed.
The 8 main metabolic routes are shown in Fig. 4. The main
metabolite of (–)clau was 7-hydroxyl-clau, while the main
metabolite of (þ)clau was 4-hydroxyl-clau.
7.5. Elimination of clau
Sixty hour after administration of single dose of each enantiomer
(80 mg/kg), bile, urine and feces of rats were collected and
analyzed by HPLC. Results revealed that (–)clau and its metabo-
lites were excreted via gastrointestinal route and (þ)clau and its
metabolites via biliary route. The total percentage of three
excretory pathways was 20% for (–)clau and 25.9% for (þ)clau,Figure 4 The main metabolites of (–) and (þ)clau.suggesting that the majority of parent drug may be transferred into
metabolites which were expelled from the body or further
transferred into other forms of metabolites.
7.6. Metabolism of clau enantiomers
To identify which cytochrome P450 (CYP) isoform(s) are respon-
sible for the metabolism of clau enantiomers in rats, the effect of
various CYP isoform inducers and inhibitors on the formation of
clau metabolites was investigated with liver microsomes. Induction
and inhibition studies suggested that CYP3A was the predominant
isoform responsible for the metabolism of clau enantiomers
(Fig. 4).8. Conclusions
In conclusion, synthetic (–)clau, one of the optical isomers of clau
isolated from C. lansium, is a new type of anti-dementia agent,
characteristic by improved learning and memory in normal and
memory impairment rodents, increased synaptic plasticity in both
efﬁcacy and structure, and decreased apoptosis with high phos-
phorylation of tau protein. Owing to this multi-target effect, the
low toxicity and unique mechanism of action suggests that it is a
promising drug for treatment of neurodegenerative diseases and
many kinds of memory impairment.References
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